Amgen Goes Public With Kyprolis Value Data To Supplement ICER Review
This article was originally published in The Pink Sheet Daily
Executive Summary
In an unusually public discussion of drug value, the company releases its economic analysis for Kyprolis in advance of an ICER technology assessment of that drug and others for multiple myeloma. Amgen's Martin Zagari says manufacturers must find new ways to present alternative, "rigorous" points of view.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.